New shot shows promise for Hard-to-Treat blood cancer
NCT ID NCT06630806
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tests a new antibody drug (SAR446523) given as a shot under the skin for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to find the safest and most effective dose, and to see if it can shrink tumors. About 87 adults will take part in two phases: first to find the right dose, then to compare two dose schedules.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hackensack Meridian Health - Hackensack University Medical Center- Site Number : 8400001
RECRUITINGHackensack, New Jersey, 07601, United States
-
Investigational Site Number : 0360001
RECRUITINGWollongong, New South Wales, 2500, Australia
-
Investigational Site Number : 0360002
RECRUITINGMelbourne, Victoria, 3065, Australia
-
Investigational Site Number : 1240001
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
-
Investigational Site Number : 1240002
RECRUITINGSherbrooke, Quebec, J1H 5N4, Canada
-
Investigational Site Number : 1240005
RECRUITINGVancouver, British Columbia, V5Z 1L3, Canada
-
Investigational Site Number : 2500001
RECRUITINGNantes, 44093, France
-
Investigational Site Number : 2500002
RECRUITINGLille, 59037, France
-
Investigational Site Number : 3760001
RECRUITINGTel Aviv, Malopolskie, 6423906, Israel
-
Investigational Site Number : 3760002
RECRUITINGJerusalem, 9112001, Israel
-
Investigational Site Number : 3760004
RECRUITINGHaifa, 3109601, Israel
-
Investigational Site Number : 3800001
RECRUITINGRozzano, Milano, 20089, Italy
-
Investigational Site Number : 3800002
RECRUITINGTorette, Ancona, 60020, Italy
-
Investigational Site Number : 7240001
RECRUITINGMadrid, 28040, Spain
-
Investigational Site Number : 7240002
RECRUITINGBarcelona, Barcelona [Barcelona], 08035, Spain
-
Mayo Clinic in Arizona - Phoenix- Site Number : 8400005
RECRUITINGPhoenix, Arizona, 85054, United States
-
Mayo Clinic in Florida- Site Number : 8400003
RECRUITINGJacksonville, Florida, 32224, United States
-
Mayo Clinic in Rochester - Minnesota- Site Number : 8400004
RECRUITINGRochester, Minnesota, 55905, United States
-
Thomas Jefferson University Hospital- Site Number : 8400002
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.